Subject(s)
COVID-19 , Eye Infections, Fungal , Mucormycosis , Retinal Artery Occlusion , SARS-CoV-2 , Humans , COVID-19/complications , COVID-19/diagnosis , Mucormycosis/diagnosis , Mucormycosis/complications , Retinal Artery Occlusion/diagnosis , Retinal Artery Occlusion/microbiology , Retinal Artery Occlusion/etiology , Eye Infections, Fungal/diagnosis , Eye Infections, Fungal/microbiology , Eye Infections, Fungal/complications , Orbital Diseases/diagnosis , Orbital Diseases/microbiology , Orbital Diseases/etiologyABSTRACT
Rhino orbital Mucormycosis caused by filamentous fungus of mucoraceae family was considered a rare disease affecting immunocompromised and diabetics with ketoacidosis until the recent COVID 19 pandemic. We are presenting a series of six cases of Rhino orbital cerebral Mucormycosis with central retinal artery occlusion. All six cases had common history of COVID 19 infection in recent past with sinusitis, proptosis and total ophthalmoplegia with central retinal artery occlusion on presentation. MR imaging showed invasive pan sinusitis with orbital and cerebral involvement. Urgent debridement was done and histopathological examination showed broad, filamentous aseptate fungi suggestive of Mucormycosis. All patients inspite of intravenous Amphotericin B with local debridement did not show any improvement and expired within a week of presentation. Hence our study shows poor prognosis of post covid 19 associated Mucormycosis with central retinal artery occlusion.
Subject(s)
COVID-19 , Mucormycosis , Orbital Diseases , Retinal Artery Occlusion , Sinusitis , Humans , Mucormycosis/complications , Mucormycosis/diagnosis , Mucormycosis/therapy , Orbital Diseases/diagnosis , Orbital Diseases/etiology , Orbital Diseases/therapy , COVID-19/complications , Sinusitis/complications , Sinusitis/diagnosis , Sinusitis/therapy , Retinal Artery Occlusion/diagnosis , Retinal Artery Occlusion/etiologyABSTRACT
Purpose: Aim of this study was to compare the efficacy of sodium hyaluronate (SH) and carboxymethyl cellulose (CMC) eye drops in treating mild to moderate dry eye disease in terms of relief of symptoms, mean change in tear film breakup time, Schirmer's test, and impression cytology of conjunctiva from baseline. Methods: An observational study was carried out during a 2-year period in our tertiary referral hospital. The study consisted of 60 patients randomly allotted to two groups to receive SH and CMC eye drops for an 8-week period. Ocular surface disease index, tear film breakup time, and Schirmer's test were performed at baseline visit and 4 and 8 weeks of treatment, and impression cytology of conjunctiva was performed at baseline and 8 weeks. Results: Significant improvement in patient symptoms, tear film breakup time, and Schirmer's test from baseline was seen in both SH and CMC groups at 8 weeks posttreatment, whereas impression cytology of conjunctiva in both groups did not show significant improvement at 8 weeks of treatment. Data analysis using unpaired t-test showed comparable results. Conclusion: Both CMC and SH demonstrated equal efficacy in treating mild to moderate dry eye disease.
